Anti Amyloid Leqembi denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Leqembi as Duplicate Therapy — and Why You Can Appeal

UnitedHealthcare may issue a duplicate-therapy denial when it identifies another Alzheimer's medication already on the patient's profile and concludes a second agent is redundant. For Leqembi (lecanemab) this rationale is almost always clinically incorrect: existing symptomatic medications for Alzheimer's disease operate through entirely different mechanisms than anti-amyloid immunotherapy. Lecanemab does not duplicate a symptomatic agent — it acts on the underlying amyloid pathology.

## Why This Denial Is Appealable

A duplicate-therapy determination must be based on accurate clinical classification. When the two therapies have non-overlapping mechanisms and serve distinct treatment goals, the duplicate-therapy rationale fails on its face. Under ACA §2719 and ERISA §503, UHC must provide a full internal appeal process and access to independent external review. You have up to 180 days from the denial notice to file an internal appeal, and the external review window under federal rules is approximately four months from exhaustion of internal remedies. Request expedited review if clinical urgency exists.

## What to Gather

• Mechanism comparison: Have the prescriber document in writing that the concurrent medication(s) and lecanemab have distinct mechanisms and non-overlapping treatment goals, citing the FDA prescribing information for each.
• Diagnosis and clinical records: Confirm the Alzheimer's diagnosis, disease stage, and amyloid-positive status.
• Prescriber medical-necessity letter: Explain why both the existing medication and lecanemab are appropriate simultaneously, with reference to current neurology guideline organization recommendations.
• Medication list with clinical rationale: Document each current medication, its class, its mechanism, and its clinical purpose.

## Criteria-Mapping Approach

Request UHC's published policy on duplicate-therapy criteria. Identify the exact definition of "duplicate" it applies. Then demonstrate, using the FDA prescribing labels for each drug, that lecanemab and the existing agent do not meet that definition — they target distinct molecular pathways with distinct therapeutic objectives. A letter from the treating neurologist explicitly stating these drugs are not duplicates and that combination use reflects current standard of care is central to this appeal.